{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:46:34Z","timestamp":1777387594321,"version":"3.51.4"},"publisher-location":"Singapore","reference-count":139,"publisher":"Springer Singapore","isbn-type":[{"value":"9789811602665","type":"print"},{"value":"9789811602672","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-981-16-0267-2_3","type":"book-chapter","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T20:02:36Z","timestamp":1626206556000},"page":"63-95","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and Their Inhibition"],"prefix":"10.1007","author":[{"given":"Murugesan","family":"Vanangamudi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramod C.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. E. Maida","family":"Engels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthilkumar","family":"Palaniappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vigneshwaran","family":"Namasivayam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"3_CR1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1126\/science.6601823","volume":"220","author":"RC Gallo","year":"1983","unstructured":"Gallo RC, Sarin PS, Gelmann EP, Robert-Guroff M, Richardson E, Kalyanaraman VS, Mann D, Sidhu GD, Stahl RE, Zolla-Pazner S et al (1983) Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220:865\u2013867","journal-title":"Science"},{"key":"3_CR2","unstructured":"UNAIDS (2019)\u00a0UNAIDS data 2019,\u00a0https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2019-UNAIDS-data_en.pdf"},{"key":"3_CR3","first-page":"1","volume":"30","author":"GM Shaw","year":"1984","unstructured":"Shaw GM, Broder S, Essex M, Gallo RC (1984) Human T-cell leukemia virus: its discovery and role in leukemogenesis and immunosuppression. Adv Intern Med 30:1\u201327","journal-title":"Adv Intern Med"},{"key":"3_CR4","first-page":"243","volume":"389","author":"DS Goodsell","year":"2015","unstructured":"Goodsell DS (2015) Illustrations of the HIV life cycle. Curr Top Microbiol Immunol 389:243\u2013252","journal-title":"Curr Top Microbiol Immunol"},{"key":"3_CR5","volume":"10","author":"A Neumann","year":"2020","unstructured":"Neumann A, M\u00fcller CE, Namasivayam V (2020) P2Y1-like nucleotide receptors\u2014structures, molecular modeling, mutagenesis, and oligomerization. Science 10:e1464","journal-title":"Science"},{"key":"3_CR6","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1016\/j.bmc.2014.04.018","volume":"22","author":"V Murugesan","year":"2014","unstructured":"Murugesan V, Makwana N, Suryawanshi R, Saxena R, Tripathi R, Paranjape R, Kulkarni S, Katti SB (2014) Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem 22:3159\u20133170","journal-title":"Bioorg Med Chem"},{"key":"3_CR7","doi-asserted-by":"publisher","first-page":"6919","DOI":"10.1016\/j.bmc.2011.09.018","volume":"19","author":"V Murugesan","year":"2011","unstructured":"Murugesan V, Tiwari VS, Saxena R, Tripathi R, Paranjape R, Kulkarni S, Makwana N, Suryawanshi R, Katti SB (2011) Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem 19:6919\u20136926","journal-title":"Bioorg Med Chem"},{"key":"3_CR8","volume":"8","author":"V Poongavanam","year":"2018","unstructured":"Poongavanam V, Namasivayam V, Vanangamudi M, Al Shamaileh H, Veedu RN, Kihlberg J, Murugan NA (2018) Integrative approaches in HIV-1 non-nucleoside reverse transcriptase inhibitor design. WIREs 8:e1328","journal-title":"WIREs"},{"key":"3_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0092-8674(00)80205-6","volume":"89","author":"DC Chan","year":"1997","unstructured":"Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263\u2013273","journal-title":"Cell"},{"key":"3_CR10","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/nsb1295-1075","volume":"2","author":"M Lu","year":"1995","unstructured":"Lu M, Blacklow SC, Kim PS (1995) A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 2:1075\u20131082","journal-title":"Nat Struct Biol"},{"key":"3_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1083\/jcb.151.2.413","volume":"151","author":"GB Melikyan","year":"2000","unstructured":"Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS (2000) Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 151:413\u2013423","journal-title":"J Cell Biol"},{"key":"3_CR12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.sbi.2007.03.008","volume":"17","author":"KH Roux","year":"2007","unstructured":"Roux KH, Taylor KA (2007) AIDS virus envelope spike structure. Curr Opin Struct Biol 17:244\u2013252","journal-title":"Curr Opin Struct Biol"},{"key":"3_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11908-001-0064-x","volume":"3","author":"GD Tomaras","year":"2001","unstructured":"Tomaras GD, Greenberg ML (2001) Mechanisms for HIV-1 entry: current strategies to interfere with this step. Curr Infect Dis Rep 3:93\u201399","journal-title":"Curr Infect Dis Rep"},{"key":"3_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jcv.2005.02.004","volume":"34","author":"E Poveda","year":"2005","unstructured":"Poveda E, Rod\u00e9s B, Lebel-Binay S, Faudon JL, Jimenez V, Soriano V (2005) Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. J Clin Virol 34:295\u2013301","journal-title":"J Clin Virol"},{"key":"3_CR15","doi-asserted-by":"crossref","unstructured":"Wild C, Greenwell T, Matthews T (1993) A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 9:1051\u20131053","DOI":"10.1089\/aid.1993.9.1051"},{"key":"3_CR16","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","volume":"49","author":"P Dorr","year":"2005","unstructured":"Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C et al (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49:4721\u20134732","journal-title":"Antimicrob Agents Chemother"},{"key":"3_CR17","doi-asserted-by":"crossref","unstructured":"Beccari MV, Mogle BT, Sidman EF, Mastro KA, Asiago-Reddy E, Kufel WD (2019) Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection. Antimicrob Agents Chemother 63:e00110-19","DOI":"10.1128\/AAC.00110-19"},{"key":"3_CR18","doi-asserted-by":"publisher","first-page":"40841","DOI":"10.1074\/jbc.R112.406272","volume":"287","author":"R Blumenthal","year":"2012","unstructured":"Blumenthal R, Durell S, Viard M (2012) HIV entry and envelope glycoprotein-mediated fusion. J Biol Chem 287:40841\u201340849","journal-title":"J Biol Chem"},{"key":"3_CR19","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.3389\/fmicb.2017.02323","volume":"8","author":"SA Iacob","year":"2017","unstructured":"Iacob SA, Iacob DG (2017) Ibalizumab targeting CD4 receptors, an emerging molecule in HIV therapy. Front Microbiol 8:2323","journal-title":"Front Microbiol"},{"key":"3_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1021\/acs.jmedchem.7b01337","volume":"61","author":"NA Meanwell","year":"2018","unstructured":"Meanwell NA, Krystal MR, Nowicka-Sans B, Langley DR, Conlon DA, Eastgate MD, Grasela DM, Timmins P, Wang T, Kadow JF (2018) Inhibitors of HIV-1 attachment: the discovery and development of temsavir and its prodrug fostemsavir. J Med Chem 61:62\u201380","journal-title":"J Med Chem"},{"key":"3_CR21","doi-asserted-by":"publisher","first-page":"6308","DOI":"10.1021\/acs.jmedchem.8b00759","volume":"61","author":"T Wang","year":"2018","unstructured":"Wang T, Ueda Y, Zhang Z, Yin Z, Matiskella J, Pearce BC, Yang Z, Zheng M, Parker DD, Yamanaka GA et al (2018) Discovery of the human immunodeficiency virus type 1 (HIV-1) attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir. J Med Chem 61:6308\u20136327","journal-title":"J Med Chem"},{"key":"3_CR22","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","volume":"382","author":"M Kozal","year":"2020","unstructured":"Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, Grinsztejn B, Diaz R, Castagna A, Kumar P et al (2020) Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. N Engl J Med 382:1232\u20131243","journal-title":"N Engl J Med"},{"key":"3_CR23","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1093\/jac\/dkaa073","volume":"75","author":"Y Bouba","year":"2020","unstructured":"Bouba Y, Berno G, Fabeni L, Carioti L, Salpini R, Aquaro S, Svicher V, Perno CF, Ceccherini-Silberstein F, Santoro MM (2020) Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir. J Antimicrob Chemother 75:1778\u20131786","journal-title":"J Antimicrob Chemother"},{"key":"3_CR24","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003495-200565070-00001","volume":"65","author":"A Castagna","year":"2005","unstructured":"Castagna A, Biswas P, Beretta A, Lazzarin A (2005) The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development. Drugs 65:879\u2013904","journal-title":"Drugs"},{"key":"3_CR25","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.2165\/00003495-200565130-00002","volume":"65","author":"JD Reeves","year":"2005","unstructured":"Reeves JD, Piefer AJ (2005) Emerging drug targets for antiretroviral therapy. Drugs 65:1747\u20131766","journal-title":"Drugs"},{"key":"3_CR26","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S0092-8674(00)81313-6","volume":"85","author":"H Choe","year":"1996","unstructured":"Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, Larosa G, Newman W et al (1996) The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135\u20131148","journal-title":"Cell"},{"key":"3_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/381661a0","volume":"381","author":"H Deng","year":"1996","unstructured":"Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM et al (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661\u2013666","journal-title":"Nature"},{"key":"3_CR28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/381667a0","volume":"381","author":"T Dragic","year":"1996","unstructured":"Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP et al (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667\u2013673","journal-title":"Nature"},{"key":"3_CR29","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.1241475","volume":"341","author":"Q Tan","year":"2013","unstructured":"Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, Li T, Ma L, Fenalti G, Li J et al (2013) Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341:1387\u20131390","journal-title":"Science"},{"key":"3_CR30","doi-asserted-by":"publisher","first-page":"9621","DOI":"10.1021\/acs.jmedchem.8b01077","volume":"61","author":"P Peng","year":"2018","unstructured":"Peng P, Chen H, Zhu Y, Wang Z, Li J, Luo RH, Wang J, Chen L, Yang LM, Jiang H et al (2018) Structure-based design of 1-heteroaryl-1,3-propanediamine derivatives as a novel series of CC-chemokine receptor 5 antagonists. J Med Chem 61:9621\u20139636","journal-title":"J Med Chem"},{"key":"3_CR31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.virol.2011.02.016","volume":"413","author":"J Labrecque","year":"2011","unstructured":"Labrecque J, Metz M, Lau G, Darkes MC, Wong RS, Bogucki D, Carpenter B, Chen G, Li T, Nan S et al (2011) HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay. Virology 413:231\u2013243","journal-title":"Virology"},{"key":"3_CR32","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jmgm.2007.12.003","volume":"26","author":"T Wang","year":"2008","unstructured":"Wang T, Duan Y (2008) Binding modes of CCR5-targetting HIV entry inhibitors: partial and full antagonists. J Mol Graph Model 26:1287\u20131295","journal-title":"J Mol Graph Model"},{"key":"3_CR33","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.immuni.2017.05.002","volume":"46","author":"Y Zheng","year":"2017","unstructured":"Zheng Y, Han GW, Abagyan R, Wu B, Stevens RC, Cherezov V, Kufareva I, Handel TM (2017) Structure of CC chemokine receptor 5 with a potent chemokine antagonist reveals mechanisms of chemokine recognition and molecular mimicry by HIV. Immunity 46:1005\u20131017","journal-title":"Immunity"},{"key":"3_CR34","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/jac\/dkl027","volume":"57","author":"V Briz","year":"2006","unstructured":"Briz V, Poveda E, Soriano V (2006) HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 57:619\u2013627","journal-title":"J Antimicrob Chemother"},{"key":"3_CR35","doi-asserted-by":"publisher","first-page":"11457","DOI":"10.1128\/JVI.01384-15","volume":"89","author":"X Jiang","year":"2015","unstructured":"Jiang X, Feyertag F, Meehan CJ, Mccormack GP, Travers SA, Craig C, Westby M, Lewis M, Robertson DL (2015) Characterizing the diverse mutational pathways associated with R5-Tropic maraviroc resistance: HIV-1 that uses the drug-bound CCR5 coreceptor. J Virol 89:11457\u201311472","journal-title":"J Virol"},{"key":"3_CR36","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3390\/v2051069","volume":"2","author":"MA Lobritz","year":"2010","unstructured":"Lobritz MA, Ratcliff AN, Arts EJ (2010) HIV-1 entry, inhibitors, and resistance. Viruses 2:1069\u20131105","journal-title":"Viruses"},{"key":"3_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.virusres.2016.12.019","volume":"234","author":"L Men\u00e9ndez-Arias","year":"2017","unstructured":"Men\u00e9ndez-Arias L, Sebasti\u00e1n-Mart\u00edn A, \u00c1lvarez M (2017) Viral reverse transcriptases. Virus Res 234:153\u2013176","journal-title":"Virus Res"},{"key":"3_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41586-018-0055-9","volume":"557","author":"KP Larsen","year":"2018","unstructured":"Larsen KP, Mathiharan YK, Kappel K, Coey AT, Chen DH, Barrero D, Madigan L, Puglisi JD, Skiniotis G, Puglisi EV (2018) Architecture of an HIV-1 reverse transcriptase initiation complex. Nature 557:118\u2013122","journal-title":"Nature"},{"key":"3_CR39","doi-asserted-by":"publisher","first-page":"7308","DOI":"10.1073\/pnas.1814170116","volume":"116","author":"K Das","year":"2019","unstructured":"Das K, Martinez SE, Destefano JJ, Arnold E (2019) Structure of HIV-1 RT\/dsRNA initiation complex prior to nucleotide incorporation. Proc Natl Acad Sci U S A 116:7308\u20137313","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR40","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1021\/bi962410z","volume":"36","author":"W Tong","year":"1997","unstructured":"Tong W, Lu CD, Sharma SK, Matsuura S, So AG, Scott WA (1997) Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. Biochemistry 36:5749\u20135757","journal-title":"Biochemistry"},{"key":"3_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104613","volume":"171","author":"E Tramontano","year":"2019","unstructured":"Tramontano E, Corona A, Men\u00e9ndez-Arias L (2019) Ribonuclease H, an unexploited target for antiviral intervention against HIV and hepatitis B virus. Antiviral Res 171:104613","journal-title":"Antiviral Res"},{"key":"3_CR42","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.4155\/fmc.13.178","volume":"5","author":"A Corona","year":"2013","unstructured":"Corona A, Masaoka T, Tocco G, Tramontano E, Le Grice SF (2013) Active site and allosteric inhibitors of the ribonuclease H activity of HIV reverse transcriptase. Future Med Chem 5:2127\u20132139","journal-title":"Future Med Chem"},{"key":"3_CR43","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1126\/science.1377403","volume":"256","author":"LA Kohlstaedt","year":"1992","unstructured":"Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783\u20131790","journal-title":"Science"},{"key":"3_CR44","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1073\/pnas.91.9.3911","volume":"91","author":"SJ Smerdon","year":"1994","unstructured":"Smerdon SJ, J\u00e4ger J, Wang J, Kohlstaedt LA, Chirino AJ, Friedman JM, Rice PA, Steitz TA (1994) Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 91:3911\u20133915","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR45","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/pro.3681","volume":"28","author":"N Bertoletti","year":"2019","unstructured":"Bertoletti N, Chan AH, Schinazi RF, Yin YW, Anderson KS (2019) Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase: first crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine. Protein Sci 28:1664\u20131675","journal-title":"Protein Sci"},{"key":"3_CR46","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/AAC.04201-14","volume":"59","author":"M Feng","year":"2015","unstructured":"Feng M, Wang D, Grobler JA, Hazuda DJ, Miller MD, Lai MT (2015) In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother 59:590\u2013598","journal-title":"Antimicrob Agents Chemother"},{"key":"3_CR47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1021\/acsinfecdis.9b00178","volume":"6","author":"C Hwang","year":"2020","unstructured":"Hwang C, Lai MT, Hazuda D (2020) Rational design of doravirine: from bench to patients. ACS Infect Dis 6:64\u201373","journal-title":"ACS Infect Dis"},{"key":"3_CR48","doi-asserted-by":"publisher","first-page":"7920","DOI":"10.1021\/jm2010173","volume":"54","author":"R Gomez","year":"2011","unstructured":"Gomez R, Jolly SJ, Williams T, Vacca JP, Torrent M, McGaughey G, Lai MT, Felock P, Munshi V, Distefano D et al (2011) Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase. J Med Chem 54:7920\u20137933","journal-title":"J Med Chem"},{"key":"3_CR49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3851\/IMP1607","volume":"20","author":"G La Regina","year":"2010","unstructured":"La Regina G, Coluccia A, Silvestri R (2010) Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors. Antivir Chem Chemother 20:213\u2013237","journal-title":"Antivir Chem Chemother"},{"key":"3_CR50","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/j.bmcl.2019.06.047","volume":"29","author":"T Sasaki","year":"2019","unstructured":"Sasaki T, Gannam ZTK, Kudalkar SN, Frey KM, Lee WG, Spasov KA, Jorgensen WL, Anderson KS (2019) Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase. Bioorg Med Chem Lett 29:2182\u20132188","journal-title":"Bioorg Med Chem Lett"},{"key":"3_CR51","doi-asserted-by":"crossref","unstructured":"Yang Y, Kang D, Nguyen LA, Smithline ZB, Pannecouque C, Zhan P, Liu X, Steitz TA (2018) Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-d]pyrimidine non-nucleoside inhibitors. Elife 7:e36340","DOI":"10.7554\/eLife.36340"},{"key":"3_CR52","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.2174\/0929867324666170705122851","volume":"24","author":"M Vanangamudi","year":"2017","unstructured":"Vanangamudi M, Poongavanam V, Namasivayam V (2017) HIV-1 non-nucleoside reverse transcriptase inhibitors: SAR and lead optimization using CoMFA and CoMSIA studies (1995-2016). Curr Med Chem 24:3774\u20133812","journal-title":"Curr Med Chem"},{"key":"3_CR53","doi-asserted-by":"crossref","unstructured":"Bruccoleri A (2013) Positional adaptability in the design of mutation-resistant nonnucleoside HIV-1 reverse transcriptase inhibitors: a supramolecular perspective. AIDS Res Hum Retroviruses 29:4\u201312","DOI":"10.1089\/aid.2012.0141"},{"key":"3_CR54","doi-asserted-by":"publisher","first-page":"586401","DOI":"10.1155\/2012\/586401","volume":"2012","author":"F Esposito","year":"2012","unstructured":"Esposito F, Corona A, Tramontano E (2012) HIV-1 reverse transcriptase still remains a new drug target: structure, function, classical inhibitors, and new inhibitors with innovative mechanisms of actions. Mol Biol Int 2012:586401","journal-title":"Mol Biol Int"},{"key":"3_CR55","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1021\/jm200990c","volume":"55","author":"D Li","year":"2012","unstructured":"Li D, Zhan P, De Clercq E, Liu X (2012) Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. J Med Chem 55:3595\u20133613","journal-title":"J Med Chem"},{"key":"3_CR56","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.1707186","volume":"252","author":"JF Davies","year":"1991","unstructured":"Davies JF, Hostomska Z, Hostomsky Z, Jordan SR, Matthews DA (1991) Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science 252:88\u201395","journal-title":"Science"},{"key":"3_CR57","doi-asserted-by":"publisher","first-page":"14697","DOI":"10.1016\/S0021-9258(18)98742-9","volume":"266","author":"Z Hostomska","year":"1991","unstructured":"Hostomska Z, Matthews DA, Davies JF, Nodes BR, Hostomsky Z (1991) Proteolytic release and crystallization of the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem 266:14697\u201314702","journal-title":"J Biol Chem"},{"key":"3_CR58","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1073\/pnas.1719746115","volume":"115","author":"L Tian","year":"2018","unstructured":"Tian L, Kim MS, Li H, Wang J, Yang W (2018) Structure of HIV-1 reverse transcriptase cleaving RNA in an RNA\/DNA hybrid. Proc Natl Acad Sci U S A 115:507\u2013512","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR59","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02203-17","volume":"92","author":"PL Boyer","year":"2018","unstructured":"Boyer PL, Smith SJ, Zhao XZ, Das K, Gruber K, Arnold E, Burke TR Jr, Hughes SH (2018) Developing and evaluating inhibitors against the RNase H active site of HIV-1 reverse transcriptase. J Virol 92:e02203","journal-title":"J Virol"},{"key":"3_CR60","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1021\/jm2000757","volume":"54","author":"S Chung","year":"2011","unstructured":"Chung S, Himmel DM, Jiang JK, Wojtak K, Bauman JD, Rausch JW, Wilson JA, Beutler JA, Thomas CJ, Arnold E et al (2011) Synthesis, activity, and structural analysis of novel \u03b1-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H. J Med Chem 54:4462\u20134473","journal-title":"J Med Chem"},{"key":"3_CR61","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/cbdd.13455","volume":"93","author":"P Gao","year":"2019","unstructured":"Gao P, Wang X, Sun L, Cheng X, Poongavanam V, Kongsted J, \u00c1lvarez M, Luczkowiak J, Pannecouque C, De Clercq E et al (2019) Design, synthesis, and biologic evaluation of novel galloyl derivatives as HIV-1 RNase H inhibitors. Chem Biol Drug Des 93:582\u2013589","journal-title":"Chem Biol Drug Des"},{"key":"3_CR62","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1128\/AAC.01594-10","volume":"55","author":"EB Lansdon","year":"2011","unstructured":"Lansdon EB, Liu Q, Leavitt SA, Balakrishnan M, Perry JK, Lancaster-Moyer C, Kutty N, Liu X, Squires NH, Watkins WJ et al (2011) Structural and binding analysis of pyrimidinol carboxylic acid and N-hydroxy quinazolinedione HIV-1 RNase H inhibitors. Antimicrob Agents Chemother 55:2905\u20132915","journal-title":"Antimicrob Agents Chemother"},{"key":"3_CR63","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1039\/C7MD00600D","volume":"9","author":"V Poongavanam","year":"2018","unstructured":"Poongavanam V, Corona A, Steinmann C, Scipione L, Grandi N, Pandolfi F, Di Santo R, Costi R, Esposito F, Tramontano E et al (2018) Structure-guided approach identifies a novel class of HIV-1 ribonuclease H inhibitors: binding mode insights through magnesium complexation and site-directed mutagenesis studies. Med Chem Commun 9:562\u2013575","journal-title":"Med Chem Commun"},{"key":"3_CR64","doi-asserted-by":"crossref","unstructured":"Kirby KA, Myshakina NA, Christen MT, Chen YL, Schmidt HA, Huber AD, Xi Z, Kim S, Rao RK, Kramer ST et al (2017) A 2-hydroxyisoquinoline-1,3-dione active-site RNase H inhibitor binds in multiple modes to HIV-1 reverse transcriptase. Antimicrob Agents Chemother 61:e01351-17","DOI":"10.1128\/AAC.01351-17"},{"key":"3_CR65","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1021\/cb600303y","volume":"1","author":"DM Himmel","year":"2006","unstructured":"Himmel DM, Sarafianos SG, Dharmasena S, Hossain MM, Mccoy-Simandle K, Ilina T, Clark AD, Knight JL, Julias JG, Clark PK et al (2006) HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem Biol 1:702\u2013712","journal-title":"ACS Chem Biol"},{"key":"3_CR66","doi-asserted-by":"publisher","first-page":"15908","DOI":"10.1021\/bi981200e","volume":"37","author":"D Arion","year":"1998","unstructured":"Arion D, Kaushik N, Mccormick S, Borkow G, Parniak MA (1998) Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37:15908\u201315917","journal-title":"Biochemistry"},{"key":"3_CR67","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0022-2836(02)00911-7","volume":"323","author":"A Mas","year":"2002","unstructured":"Mas A, V\u00e1zquez-Alvarez BM, Domingo E, Men\u00e9ndez-Arias L (2002) Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. J Mol Biol 323:181\u2013197","journal-title":"J Mol Biol"},{"key":"3_CR68","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1097-2765(00)80185-9","volume":"4","author":"PR Meyer","year":"1999","unstructured":"Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA (1999) A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 4:35\u201343","journal-title":"Mol Cell"},{"key":"3_CR69","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1006\/jmbi.2001.4648","volume":"309","author":"Y Hsiou","year":"2001","unstructured":"Hsiou Y, Ding J, Das K, Clark AD Jr, Boyer PL, Lewi P, Janssen PA, Kleim JP, R\u00f6sner M, Hughes SH et al (2001) The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol 309:437\u2013445","journal-title":"J Mol Biol"},{"key":"3_CR70","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1006\/jmbi.2001.4988","volume":"312","author":"J Ren","year":"2001","unstructured":"Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S, Stuart DI, Stammers DK (2001) Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J Mol Biol 312:795\u2013805","journal-title":"J Mol Biol"},{"key":"3_CR71","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bioorg.2017.02.007","volume":"71","author":"R Suryawanshi","year":"2017","unstructured":"Suryawanshi R, Jadhav S, Makwana N, Desai D, Chaturbhuj D, Sonawani A, Idicula-Thomas S, Murugesan V, Katti SB, Tripathy S et al (2017) Evaluation of 4-thiazolidinone derivatives as potential reverse transcriptase inhibitors against HIV-1 drug resistant strains. Bioorg Chem 71:211\u2013218","journal-title":"Bioorg Chem"},{"key":"3_CR72","doi-asserted-by":"crossref","unstructured":"Diphoko T, Gaseitsiwe S, Kasvosve I, Moyo S, Okatch H, Musonda R, Wainberg M, Makhema J, Marlink R, Novitsky V et al (2018) Prevalence of rilpivirine and etravirine resistance mutations in HIV-1 subtype C-infected patients failing nevirapine or efavirenz-based combination antiretroviral therapy in Botswana. AIDS Res Hum Retroviruses 34:667\u2013671","DOI":"10.1089\/aid.2017.0135"},{"key":"3_CR73","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","volume":"62","author":"V Namasivayam","year":"2019","unstructured":"Namasivayam V, Vanangamudi M, Kramer VG, Kurup S, Zhan P, Liu X, Kongsted J, Byrareddy SN (2019) The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic. J Med Chem 62:4851\u20134883","journal-title":"J Med Chem"},{"key":"3_CR74","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1128\/AAC.02650-15","volume":"60","author":"M Feng","year":"2016","unstructured":"Feng M, Sachs NA, Xu M, Grobler J, Blair W, Hazuda DJ, Miller MD, Lai MT (2016) Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations. Antimicrob Agents Chemother 60:2241\u20132247","journal-title":"Antimicrob Agents Chemother"},{"key":"3_CR75","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0167-7799(97)01016-0","volume":"15","author":"M Thomas","year":"1997","unstructured":"Thomas M, Brady L (1997) HIV integrase: a target for AIDS therapeutics. Trends Biotechnol 15:167\u2013172","journal-title":"Trends Biotechnol"},{"key":"3_CR76","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1128\/jvi.68.6.3896-3907.1994","volume":"68","author":"SA Chow","year":"1994","unstructured":"Chow SA, Brown PO (1994) Substrate features important for recognition and catalysis by human immunodeficiency virus type 1 integrase identified by using novel DNA substrates. J Virol 68:3896\u20133907","journal-title":"J Virol"},{"key":"3_CR77","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/0092-8674(91)90297-C","volume":"67","author":"A Engelman","year":"1991","unstructured":"Engelman A, Mizuuchi K, Craigie R (1991) HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 67:1211\u20131221","journal-title":"Cell"},{"issue":"Suppl 12","key":"3_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0213-005X(08)76565-0","volume":"26","author":"JM Gatell","year":"2008","unstructured":"Gatell JM (2008) Raltegravir: the first HIV integrase inhibitor. Introduction. Enferm Infect Microbiol Clin 26(Suppl 12):1\u20132","journal-title":"Enferm Infect Microbiol Clin"},{"key":"3_CR79","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1128\/JVI.01534-07","volume":"82","author":"K Shimura","year":"2008","unstructured":"Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M et al (2008) Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303\/GS-9137). J Virol 82:764\u2013774","journal-title":"J Virol"},{"key":"3_CR80","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1021\/jm400645w","volume":"56","author":"BA Johns","year":"2013","unstructured":"Johns BA, Kawasuji T, Weatherhead JG, Taishi T, Temelkoff DP, Yoshida H, Akiyama T, Taoda Y, Murai H, Kiyama R et al (2013) Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S\/GSK1349572) and (S\/GSK1265744). J Med Chem 56:5901\u20135916","journal-title":"J Med Chem"},{"key":"3_CR81","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-018-0896-4","volume":"78","author":"A Markham","year":"2018","unstructured":"Markham A (2018) Bictegravir: first global approval. Drugs 78:601\u2013606","journal-title":"Drugs"},{"key":"3_CR82","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12977-018-0440-3","volume":"15","author":"M Oliveira","year":"2018","unstructured":"Oliveira M, Ibanescu RI, Anstett K, M\u00e9spl\u00e8de T, Routy JP, Robbins MA, Brenner BG (2018) Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology 15:56","journal-title":"Retrovirology"},{"key":"3_CR83","doi-asserted-by":"crossref","unstructured":"Choi E, Mallareddy JR, Lu D, Kolluru S (2018) Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase. Future Sci OA 4:FSO338","DOI":"10.4155\/fsoa-2018-0060"},{"key":"3_CR84","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jmb.2006.10.094","volume":"365","author":"K Busschots","year":"2007","unstructured":"Busschots K, Voet A, De Maeyer M, Rain JC, Emiliani S, Benarous R, Desender L, Debyser Z, Christ F (2007) Identification of the LEDGF\/p75 binding site in HIV-1 integrase. J Mol Biol 365:1480\u20131492","journal-title":"J Mol Biol"},{"key":"3_CR85","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nsmb937","volume":"12","author":"P Cherepanov","year":"2005","unstructured":"Cherepanov P, Sun ZY, Rahman S, Maertens G, Wagner G, Engelman A (2005) Solution structure of the HIV-1 integrase-binding domain in LEDGF\/p75. Nat Struct Mol Biol 12:526\u2013532","journal-title":"Nat Struct Mol Biol"},{"key":"3_CR86","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2174\/138955711796268787","volume":"11","author":"L De Luca","year":"2011","unstructured":"De Luca L, Ferro S, Morreale F, Chimirri A (2011) Inhibition of the interaction between HIV-1 integrase and its cofactor LEDGF\/p75: a promising approach in anti-retroviral therapy. Mini Rev Med Chem 11:714\u2013727","journal-title":"Mini Rev Med Chem"},{"key":"3_CR87","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1126\/science.1132319","volume":"314","author":"M Llano","year":"2006","unstructured":"Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, Walker WH, Teo W, Poeschla EM (2006) An essential role for LEDGF\/p75 in HIV integration. Science 314:461\u2013464","journal-title":"Science"},{"key":"3_CR88","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature08784","volume":"464","author":"S Hare","year":"2010","unstructured":"Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P (2010) Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464:232\u2013236","journal-title":"Nature"},{"key":"3_CR89","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nsb0797-567","volume":"4","author":"M Cai","year":"1997","unstructured":"Cai M, Zheng R, Caffrey M, Craigie R, Clore GM, Gronenborn AM (1997) Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat Struct Biol 4:567\u2013577","journal-title":"Nat Struct Biol"},{"key":"3_CR90","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2174\/1568026043388547","volume":"4","author":"TK Chiu","year":"2004","unstructured":"Chiu TK, Davies DR (2004) Structure and function of HIV-1 integrase. Curr Top Med Chem 4:965\u2013977","journal-title":"Curr Top Med Chem"},{"key":"3_CR91","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nsb0995-807","volume":"2","author":"AP Eijkelenboom","year":"1995","unstructured":"Eijkelenboom AP, Lutzke RA, Boelens R, Plasterk RH, Kaptein R, H\u00e5rd K (1995) The DNA-binding domain of HIV-1 integrase has an SH3-like fold. Nat Struct Biol 2:807\u2013810","journal-title":"Nat Struct Biol"},{"key":"3_CR92","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1124\/mol.111.073189","volume":"80","author":"S Hare","year":"2011","unstructured":"Hare S, Smith SJ, M\u00e9tifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, Cherepanov P (2011) Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S\/GSK1349572). Mol Pharmacol 80:565\u2013572","journal-title":"Mol Pharmacol"},{"key":"3_CR93","doi-asserted-by":"publisher","first-page":"20057","DOI":"10.1073\/pnas.1010246107","volume":"107","author":"S Hare","year":"2010","unstructured":"Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P (2010) Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A 107:20057\u201320062","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR94","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1021\/cb300471n","volume":"8","author":"M M\u00e9tifiot","year":"2013","unstructured":"M\u00e9tifiot M, Maddali K, Johnson BC, Hare S, Smith SJ, Zhao XZ, Marchand C, Burke TR Jr, Hughes SH, Cherepanov P et al (2013) Activities, crystal structures, and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase. ACS Chem Biol 8:209\u2013217","journal-title":"ACS Chem Biol"},{"key":"3_CR95","doi-asserted-by":"publisher","first-page":"8154","DOI":"10.1021\/acs.jmedchem.5b01037","volume":"58","author":"IT Raheem","year":"2015","unstructured":"Raheem IT, Walji AM, Klein D, Sanders JM, Powell DA, Abeywickrema P, Barbe G, Bennet A, Childers K, Christensen M et al (2015) Discovery of 2-pyridinone animals: a prodrug strategy to advance a second generation of HIV-1 integrase strand transfer inhibitors. J Med Chem 58:8154\u20138165","journal-title":"J Med Chem"},{"key":"3_CR96","doi-asserted-by":"publisher","first-page":"7315","DOI":"10.1021\/acs.jmedchem.7b00596","volume":"60","author":"XZ Zhao","year":"2017","unstructured":"Zhao XZ, Smith SJ, Maskell DP, M\u00e9tifiot M, Pye VE, Fesen K, Marchand C, Pommier Y, Cherepanov P, Hughes SH et al (2017) Structure-guided optimization of HIV integrase strand transfer inhibitors. J Med Chem 60:7315\u20137332","journal-title":"J Med Chem"},{"key":"3_CR97","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrmicro2747","volume":"10","author":"A Engelman","year":"2012","unstructured":"Engelman A, Cherepanov P (2012) The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol 10:279\u2013290","journal-title":"Nat Rev Microbiol"},{"key":"3_CR98","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nature09517","volume":"468","author":"GN Maertens","year":"2010","unstructured":"Maertens GN, Hare S, Cherepanov P (2010) The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature 468:326\u2013329","journal-title":"Nature"},{"key":"3_CR99","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1021\/ml500002n","volume":"5","author":"LD Fader","year":"2014","unstructured":"Fader LD, Malenfant E, Parisien M, Carson R, Bilodeau F, Landry S, Pesant M, Brochu C, Morin S, Chabot C et al (2014) Discovery of BI 224436, a noncatalytic site integrase inhibitor (NCINI) of HIV-1. ACS Med Chem Lett 5:422\u2013427","journal-title":"ACS Med Chem Lett"},{"key":"3_CR100","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1128\/AAC.02719-13","volume":"58","author":"C Fenwick","year":"2014","unstructured":"Fenwick C, Amad M, Bailey MD, Bethell R, B\u00f6s M, Bonneau P, Cordingley M, Coulombe R, Duan J, Edwards P et al (2014) Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor. Antimicrob Agents Chemother 58:3233\u20133244","journal-title":"Antimicrob Agents Chemother"},{"key":"3_CR101","doi-asserted-by":"crossref","unstructured":"Koneru PC, Francis AC, Deng N, Rebensburg SV, Hoyte AC, Lindenberger J, Adu-Ampratwum D, Larue RC, Wempe MF, Engelman AN et al (2019) HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors. Elife 8:e46344","DOI":"10.7554\/eLife.46344"},{"key":"3_CR102","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ejmech.2019.06.058","volume":"179","author":"MSA Gill","year":"2019","unstructured":"Gill MSA, Hassan SS, Ahemad N (2019) Evolution of HIV-1 reverse transcriptase and integrase dual inhibitors: recent advances and developments. Eur J Med Chem 179:423\u2013448","journal-title":"Eur J Med Chem"},{"key":"3_CR103","doi-asserted-by":"publisher","first-page":"11440","DOI":"10.1128\/JVI.01168-09","volume":"83","author":"S Fransen","year":"2009","unstructured":"Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M, Petropoulos CJ, Huang W (2009) Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 83:11440\u201311446","journal-title":"J Virol"},{"key":"3_CR104","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1128\/AAC.01228-07","volume":"52","author":"I Malet","year":"2008","unstructured":"Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF et al (2008) Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 52:1351\u20131358","journal-title":"Antimicrob Agents Chemother"},{"key":"3_CR105","doi-asserted-by":"crossref","unstructured":"Margot NA, Hluhanich RM, Jones GS, Andreatta KN, Tsiang M, Mccoll DJ, White KL, Miller MD (2012) In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res 93:288\u2013296","DOI":"10.1016\/j.antiviral.2011.12.008"},{"key":"3_CR106","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3390\/v2071347","volume":"2","author":"M M\u00e9tifiot","year":"2010","unstructured":"M\u00e9tifiot M, Marchand C, Maddali K, Pommier Y (2010) Resistance to integrase inhibitors. Viruses 2:1347\u20131366","journal-title":"Viruses"},{"key":"3_CR107","doi-asserted-by":"crossref","unstructured":"Men\u00e9ndez-Arias L (2013) Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res 98:93\u2013120","DOI":"10.1016\/j.antiviral.2013.01.007"},{"key":"3_CR108","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","volume":"14","author":"K Anstett","year":"2017","unstructured":"Anstett K, Brenner B, Mesplede T, Wainberg MA (2017) HIV drug resistance against strand transfer integrase inhibitors. Retrovirology 14:36","journal-title":"Retrovirology"},{"key":"3_CR109","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1126\/science.2548279","volume":"245","author":"A Wlodawer","year":"1989","unstructured":"Wlodawer A, Miller M, Jask\u00f3lski M, Sathyanarayana BK, Baldwin E, Weber IT, Selk LM, Clawson L, Schneider J, Kent SB (1989) Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245:616\u2013621","journal-title":"Science"},{"key":"3_CR110","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1126\/science.2183354","volume":"248","author":"NA Roberts","year":"1990","unstructured":"Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB, Galpin SA, Handa BK, Kay J, Kr\u00f6hn A et al (1990) Rational design of peptide-based HIV proteinase inhibitors. Science 248:358\u2013361","journal-title":"Science"},{"key":"3_CR111","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1021\/ar8000519","volume":"41","author":"YS Tsantrizos","year":"2008","unstructured":"Tsantrizos YS (2008) Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus. Acc Chem Res 41:1252\u20131263","journal-title":"Acc Chem Res"},{"key":"3_CR112","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1128\/AAC.42.12.3218","volume":"42","author":"HL Sham","year":"1998","unstructured":"Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Stewart K, Lal R, Hsu A et al (1998) ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 42:3218\u20133224","journal-title":"Antimicrob Agents Chemother"},{"key":"3_CR113","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1021\/jm970873c","volume":"41","author":"G Bold","year":"1998","unstructured":"Bold G, F\u00e4ssler A, Capraro HG, Cozens R, Klimkait T, Lazdins J, Mestan J, Poncioni B, R\u00f6sel J, Stover D et al (1998) New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J Med Chem 41:3387\u20133401","journal-title":"J Med Chem"},{"key":"3_CR114","doi-asserted-by":"crossref","unstructured":"Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG (2005) Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res 68:27\u201335","DOI":"10.1016\/j.antiviral.2005.07.003"},{"key":"3_CR115","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-013-0159-3","volume":"74","author":"ED Deeks","year":"2014","unstructured":"Deeks ED (2014) Darunavir: a review of its use in the management of HIV-1 infection. Drugs 74:99\u2013125","journal-title":"Drugs"},{"key":"3_CR116","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1126\/science.2686029","volume":"246","author":"M Miller","year":"1989","unstructured":"Miller M, Schneider J, Sathyanarayana BK, Toth MV, Marshall GR, Clawson L, Selk L, Kent SB, Wlodawer A (1989) Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science 246:1149\u20131152","journal-title":"Science"},{"key":"3_CR117","doi-asserted-by":"publisher","first-page":"8805","DOI":"10.1073\/pnas.87.22.8805","volume":"87","author":"AL Swain","year":"1990","unstructured":"Swain AL, Miller MM, Green J, Rich DH, Schneider J, Kent SB, Wlodawer A (1990) X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. Proc Natl Acad Sci U S A 87:8805\u20138809","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR118","doi-asserted-by":"publisher","first-page":"13103","DOI":"10.1016\/S0021-9258(19)38625-9","volume":"268","author":"AM Mulichak","year":"1993","unstructured":"Mulichak AM, Hui JO, Tomasselli AG, Heinrikson RL, Curry KA, Tomich CS, Thaisrivongs S, Sawyer TK, Watenpaugh KD (1993) The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors. J Biol Chem 268:13103\u201313109","journal-title":"J Biol Chem"},{"key":"3_CR119","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1039\/b208248a","volume":"1","author":"A Brik","year":"2003","unstructured":"Brik A, Wong CH (2003) HIV-1 protease: mechanism and drug discovery. Org Biomol Chem 1:5\u201314","journal-title":"Org Biomol Chem"},{"key":"3_CR120","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/342299a0","volume":"342","author":"R Lapatto","year":"1989","unstructured":"Lapatto R, Blundell T, Hemmings A, Overington J, Wilderspin A, Wood S, Merson JR, Whittle PJ, Danley DE, Geoghegan KF et al (1989) X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes. Nature 342:299\u2013302","journal-title":"Nature"},{"key":"3_CR121","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/protein\/7.3.309","volume":"7","author":"A Gustchina","year":"1994","unstructured":"Gustchina A, Sansom C, Prevost M, Richelle J, Wodak SY, Wlodawer A, Weber IT (1994) Energy calculations and analysis of HIV-1 protease-inhibitor crystal structures. Protein Eng 7:309\u2013317","journal-title":"Protein Eng"},{"key":"3_CR122","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1021\/jm00115a028","volume":"34","author":"A Krohn","year":"1991","unstructured":"Krohn A, Redshaw S, Ritchie JC, Graves BJ, Hatada MH (1991) Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J Med Chem 34:3340\u20133342","journal-title":"J Med Chem"},{"key":"3_CR123","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1021\/jm9704098","volume":"40","author":"SW Kaldor","year":"1997","unstructured":"Kaldor SW, Kalish VJ, Davies JF, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK et al (1997) Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem 40:3979\u20133985","journal-title":"J Med Chem"},{"key":"3_CR124","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1021\/jm9606608","volume":"40","author":"PL Beaulieu","year":"1997","unstructured":"Beaulieu PL, Wernic D, Abraham A, Anderson PC, Bogri T, Bousquet Y, Croteau G, Guse I, Lamarre D, Liard F et al (1997) Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere. J Med Chem 40:2164\u20132176","journal-title":"J Med Chem"},{"key":"3_CR125","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1016\/S0968-0896(02)00051-2","volume":"10","author":"V Stoll","year":"2002","unstructured":"Stoll V, Qin W, Stewart KD, Jakob C, Park C, Walter K, Simmer RL, Helfrich R, Bussiere D, Kao J et al (2002) X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease. Bioorg Med Chem 10:2803\u20132806","journal-title":"Bioorg Med Chem"},{"key":"3_CR126","doi-asserted-by":"publisher","first-page":"5468","DOI":"10.1021\/bi051886s","volume":"45","author":"JC Clemente","year":"2006","unstructured":"Clemente JC, Coman RM, Thiaville MM, Janka LK, Jeung JA, Nukoolkarn S, Govindasamy L, Agbandje-Mckenna M, Mckenna R, Leelamanit W et al (2006) Analysis of HIV-1 CRF_01 A\/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir. Biochemistry 45:5468\u20135477","journal-title":"Biochemistry"},{"key":"3_CR127","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1021\/jm9802158","volume":"41","author":"SR Turner","year":"1998","unstructured":"Turner SR, Strohbach JW, Tommasi RA, Aristoff PA, Johnson PD, Skulnick HI, Dolak LA, Seest EP, Tomich PK, Bohanon MJ et al (1998) Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 41:3467\u20133476","journal-title":"J Med Chem"},{"key":"3_CR128","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jmb.2004.02.052","volume":"338","author":"Y Tie","year":"2004","unstructured":"Tie Y, Boross PI, Wang YF, Gaddis L, Hussain AK, Leshchenko S, Ghosh AK, Louis JM, Harrison RW, Weber IT (2004) High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol 338:341\u2013352","journal-title":"J Mol Biol"},{"key":"3_CR129","doi-asserted-by":"publisher","first-page":"6599","DOI":"10.1021\/jm800283k","volume":"51","author":"AY Kovalevsky","year":"2008","unstructured":"Kovalevsky AY, Ghosh AK, Weber IT (2008) Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir. J Med Chem 51:6599\u20136603","journal-title":"J Med Chem"},{"key":"3_CR130","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jmb.2006.08.007","volume":"363","author":"AY Kovalevsky","year":"2006","unstructured":"Kovalevsky AY, Liu F, Leshchenko S, Ghosh AK, Louis JM, Harrison RW, Weber IT (2006) Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. J Mol Biol 363:161\u2013173","journal-title":"J Mol Biol"},{"key":"3_CR131","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1054-3589(07)56006-0","volume":"56","author":"H Mitsuya","year":"2008","unstructured":"Mitsuya H, Maeda K, Das D, Ghosh AK (2008) Development of protease inhibitors and the fight with drug-resistant HIV-1 variants. Adv Pharmacol 56:169\u2013197","journal-title":"Adv Pharmacol"},{"key":"3_CR132","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1086\/323604","volume":"184","author":"CF Perno","year":"2001","unstructured":"Perno CF, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, Facchi G, Pezzotti P, Cadeo G, Tositti G et al (2001) Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis 184:983\u2013991","journal-title":"J Infect Dis"},{"key":"3_CR133","doi-asserted-by":"crossref","unstructured":"Wensing AM, Van Maarseveen NM, Nijhuis M (2010) Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res 85:59\u201374","DOI":"10.1016\/j.antiviral.2009.10.003"},{"key":"3_CR134","doi-asserted-by":"publisher","first-page":"11876","DOI":"10.1021\/bi001013s","volume":"39","author":"MJ Todd","year":"2000","unstructured":"Todd MJ, Luque I, Vel\u00e1zquez-Campoy A, Freire E (2000) Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F\/I84V active site resistant mutant. Biochemistry 39:11876\u201311883","journal-title":"Biochemistry"},{"key":"3_CR135","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1021\/bi501088e","volume":"54","author":"NE Goldfarb","year":"2015","unstructured":"Goldfarb NE, Ohanessian M, Biswas S, Mcgee TD Jr, Mahon BP, Ostrov DA, Garcia J, Tang Y, Mckenna R, Roitberg A et al (2015) Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr\/Leu89Met: mechanisms for the loss of saquinavir binding potency. Biochemistry 54:422\u2013433","journal-title":"Biochemistry"},{"key":"3_CR136","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1107\/S0907444907029125","volume":"63","author":"H Heaslet","year":"2007","unstructured":"Heaslet H, Rosenfeld R, Giffin M, Lin YC, Tam K, Torbett BE, Elder JH, Mcree DE, Stout CD (2007) Conformational flexibility in the flap domains of ligand-free HIV protease. Acta Crystallogr D Biol Crystallogr 63:866\u2013875","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"3_CR137","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1111\/j.1742-4658.2005.04923.x","volume":"272","author":"Y Tie","year":"2005","unstructured":"Tie Y, Boross PI, Wang YF, Gaddis L, Liu F, Chen X, Tozser J, Harrison RW, Weber IT (2005) Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J 272:5265\u20135277","journal-title":"FEBS J"},{"key":"3_CR138","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","volume":"584","author":"JO Link","year":"2020","unstructured":"Link JO, Rhee MS, Tse WC, Zheng J, Somoza JR, Rowe W, Begley R, Chiu A, Mulato A, Hansen D et al (2020) Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature 584:614\u2013618","journal-title":"Nature"},{"key":"3_CR139","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1021\/acs.jmedchem.0c00015","volume":"63","author":"L Sun","year":"2020","unstructured":"Sun L, Dick A, Meuser ME, Huang T, Zalloum WA, Chen C-H, Cherukupalli S, Xu S, Ding X, Gao P et al (2020) Design, synthesis, and mechanism study of benzenesulfonamide-containing phenylalanine derivatives as novel HIV-1 capsid inhibitors with improved antiviral activities. J Med Chem 63:4790\u20134810","journal-title":"J Med Chem"}],"container-title":["Advances in Experimental Medicine and Biology","Antiviral Drug Discovery and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-16-0267-2_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T20:02:54Z","timestamp":1626206574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-16-0267-2_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9789811602665","9789811602672"],"references-count":139,"URL":"https:\/\/doi.org\/10.1007\/978-981-16-0267-2_3","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"14 July 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}